By Topic

Augmenting Detection of Prostate Cancer in Transrectal Ultrasound Images Using SVM and RF Time Series

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$31 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

6 Author(s)
Moradi, M. ; Dept. of Electr. & Comput. Eng., Univ. of British Columbia, Vancouver, BC, Canada ; Mousavi, P. ; Boag, A.H. ; Sauerbrei, E.E.
more authors

We propose a novel and accurate method based on ultrasound RF time series analysis and an extended version of support vector machine classification for generating probabilistic cancer maps that can augment ultrasound images of prostate and enhance the biopsy process. To form the RF time series, we record sequential ultrasound RF echoes backscattered from tissue while the imaging probe and the tissue are stationary in position. We show that RF time series acquired from agar-gelatin-based tissue mimicking phantoms, with difference only in the size of cell-mimicking microscopic glass beads, are distinguishable with statistically reliable accuracies up to 80.5%. This fact indicates that the differences in tissue microstructures affect the ultrasound RF time series features. Based on this phenomenon, in an ex vivo study involving 35 prostate specimens, we show that the features extracted from RF time series are significantly more accurate and sensitive compared to two other established categories of ultrasound-based tissue typing methods. We report an area under receiver operating characteristic curve of 0.95 in tenfold cross validation and 0.82 in leave-one-patient-out cross validation for detection of prostate cancer.

Published in:

Biomedical Engineering, IEEE Transactions on  (Volume:56 ,  Issue: 9 )